|
Market Closed -
Nasdaq
16:30:00 2026-10-22 EDT
|
5-day change | 1st Jan Change | ||
| 1.047 USD | +4.73% |
|
+12.31% | -50.83% |
| 08-20 | ABVC BioPharma, Inc. completed the Spin-Off of BioKey, Inc. | CI |
| 08-12 | ABVC BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: ABVC BioPharma, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 104.7 | 96.05 | 20.22 | 8.951 | 7.224 | 50.21 |
| Change | - | -8.3% | -78.95% | -55.74% | -19.29% | 594.95% |
| Enterprise Value (EV) 1 | 107.2 | 93.46 | 23.48 | 11.26 | 10.11 | 52.93 |
| Change | - | -12.85% | -74.88% | -52.03% | -10.26% | 423.76% |
| P/E | -10.2x | -6.62x | -1.2x | -0.48x | -1.4x | -5.42x |
| PBR | 35.8x | 11x | 6.57x | 1.09x | 6.32x | 4.66x |
| PEG | - | -2.66x | -0.82x | 0x | 0x | 0.85x |
| Capitalization / Revenue | 217x | 270x | 20.9x | 58.7x | 14.2x | - |
| EV / Revenue | 222x | 263x | 24.2x | 73.9x | 19.8x | - |
| EV / EBITDA | -12.7x | -7.99x | -1.56x | -1.38x | -2.16x | -7.43x |
| EV / EBIT | -12.6x | -7.98x | -1.55x | -1.37x | -2.15x | -7.4x |
| EV / FCF | -42.9x | -20.2x | -11.9x | -4.06x | -10.4x | 73.3x |
| FCF Yield | -2.33% | -4.96% | -8.39% | -24.6% | -9.65% | 1.36% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -5 | -5.125 | -5.2 | -2.43 | -0.42 | -0.3933 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 0.483 | 0.3558 | 0.9698 | 0.1524 | 0.5096 | - |
| EBITDA 1 | -8.469 | -11.69 | -15.09 | -8.188 | -4.673 | -7.126 |
| EBIT 1 | -8.506 | -11.71 | -15.11 | -8.217 | -4.705 | -7.151 |
| Net income 1 | -9.791 | -12.84 | -16.42 | -10.52 | -4.903 | -7.909 |
| Net Debt 1 | 2.489 | -2.597 | 3.254 | 2.311 | 2.882 | 2.727 |
| Reference price 2 | 51.000 | 33.900 | 6.250 | 1.160 | 0.590 | 2.130 |
| Nbr of stocks (in thousands) | 2,054 | 2,833 | 3,236 | 7,716 | 12,244 | 23,570 |
| Announcement Date | 3/16/21 | 3/31/22 | 3/31/23 | 3/13/24 | 4/15/25 | 3/3/26 |
1USD in Million2USD
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 27.19M | |
| 18.38x | 6.48x | 12.88x | 1.62% | 63.29B | |
| 30.22x | 7.94x | 26.49x | 0.05% | 54.89B | |
| 36.58x | 6.5x | 19.41x | 0.88% | 53.28B | |
| 35.46x | 3.44x | 14.83x | -.--% | 45.81B | |
| 50.32x | 5.82x | 31.95x | -.--% | 43.46B | |
| -19.48x | 188.5x | -20.74x | -.--% | 40.23B | |
| 29.02x | 8.23x | 21.28x | 0.37% | 33.45B | |
| 27.38x | 5.77x | 14.95x | -.--% | 23.7B | |
| 32.79x | 5.99x | 20.16x | -.--% | 23.76B | |
| Average | 26.74x | 26.52x | 15.69x | 0.32% | 38.19B | |
| Weighted average by Cap. | 26.71x | 25.51x | 15.93x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ABVC Stock
- Valuation ABVC BioPharma, Inc.
Select your edition
All financial news and data tailored to specific country editions
